MX2021011491A - Polvos secos inhalables. - Google Patents

Polvos secos inhalables.

Info

Publication number
MX2021011491A
MX2021011491A MX2021011491A MX2021011491A MX2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A MX 2021011491 A MX2021011491 A MX 2021011491A
Authority
MX
Mexico
Prior art keywords
inhalable dry
dry powders
dry powder
inhalable
cannabinoids
Prior art date
Application number
MX2021011491A
Other languages
English (en)
Inventor
Chad C Smutney
Joseph J Guarneri
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of MX2021011491A publication Critical patent/MX2021011491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente divulgación se refiere a composiciones inhalables de polvo seco que comprenden cannabinoides. En particular, las formulaciones están destinadas a ser utilizadas con inhaladores de polvo seco de un solo uso o de uso múltiple que comprenden cartuchos o cápsulas reemplazables para su administración en el pulmón profundo como agentes medicinales. Los polvos secos inhalables son útiles en el tratamiento de enfermedades y trastornos, incluido el dolor.
MX2021011491A 2019-03-22 2020-03-20 Polvos secos inhalables. MX2021011491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962822303P 2019-03-22 2019-03-22
PCT/US2020/023977 WO2020198051A1 (en) 2019-03-22 2020-03-20 Inhalable dry powders

Publications (1)

Publication Number Publication Date
MX2021011491A true MX2021011491A (es) 2022-01-18

Family

ID=72608595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011491A MX2021011491A (es) 2019-03-22 2020-03-20 Polvos secos inhalables.

Country Status (6)

Country Link
US (1) US20220241271A1 (es)
EP (1) EP3941438A4 (es)
JP (1) JP2022527054A (es)
CA (1) CA3133804A1 (es)
MX (1) MX2021011491A (es)
WO (1) WO2020198051A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230117531A1 (en) * 2020-03-19 2023-04-20 Tff Pharmaceuticals, Inc. Dried particle inhalation for delivery of cannabis
US20240050450A1 (en) * 2020-10-16 2024-02-15 Michael Ogburn Inhalable Cannabinoid Formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE285755T1 (de) * 1999-08-25 2005-01-15 Advanced Inhalation Res Inc Grosse poröse partikel erhältlich durch sprühtrocknung und geeignet zur pulmonalen anwendung
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
EP2497484A3 (en) * 2006-02-22 2012-11-07 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP3281663B8 (en) * 2008-06-13 2022-09-21 MannKind Corporation Breath powered dry powder inhaler for drug delivery
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器

Also Published As

Publication number Publication date
WO2020198051A1 (en) 2020-10-01
EP3941438A4 (en) 2022-09-21
US20220241271A1 (en) 2022-08-04
JP2022527054A (ja) 2022-05-30
CA3133804A1 (en) 2020-10-01
EP3941438A1 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
MX2023001592A (es) Inhalador de polvo seco.
WO2017046593A3 (en) An inhalable composition and an inhaler
PH12016500619A1 (en) Dry powder inhaler
ZA202103404B (en) Composition and method for treating the lungs
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
NZ767296A (en) Liquid inhalation formulation comprising rpl554
MX2021006751A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
MX2019006938A (es) Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon.
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
MX2021011491A (es) Polvos secos inhalables.
JP2018528966A5 (es)
MX2021012723A (es) Inhalador de presión positiva para entrega de medicamento inhalable y métodos para uso.
PH12014502662A1 (en) Novel dosage form and formulation of abediterol
UA118192C2 (uk) Противірусна фармацевтична композиція
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
TW200602054A (en) Use of compounds in a dry powder inhaler
WO2005041922A3 (en) Composition
IL250852B (en) Periodontal preparation
MX2020010977A (es) Procedimientos de tratamiento de infecciones fúngicas.
UA117243C2 (uk) Застосування ландіололу гідрохлориду у тривалому лікуванні тахіаритмії
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
EA200801854A1 (ru) Новые композиции
MX2021014343A (es) Una composicion de polvo inhalable de dosis fijas que comprende glicopirronio, formoterol y propionato de fluticasona.